Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus BROMPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus BROMPHENIRAMINE MALEATE.
ALLEGRA HIVES vs BROMPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Category C
Category C
Antihistamine
Antihistamine